Summary by Futu AI
Kangfang Biotechnology (Cayman) Co., Ltd Announces that the National Drug Administration (NMPA) Has Officially Accepted Its Self-Developed Bi-Specific Antibody Caetani® (Cadonilli, PD-1/CTLA-4) Combined XELOX Chemotherapy Solution for First-Line Treatment of Local Latency, Relapse or Transition of Non-Surgical Removal New Indication Application for Displaced Gastric or Gastroesophageal Associated Bladder Cancer THIS APPLICATION IS BASED ON DATA FROM PHASE III CLINICAL TRIAL AK104—302, WHICH SHOWED THAT CADONILLI COMBINED CHEMOTHERAPY SIGNIFICANTLY EXTENDED THE OVERALL SURVIVAL OF PATIENTS, AND THE SAFETY WAS CONSISTENT WITH PREVIOUS STUDIES. Stomach cancer is a common malignant tumor worldwide and we believe this new treatment will provide patients with better treatment options and have the potential to expand the market. Kaitani® was approved in June 2022 for the treatment of cervical cancer and is undergoing multiple clinical trials to explore additional indications. The Company reminds shareholders and potential investors that there is no guarantee of a successful sale of Kaitani® and that trading shares should be exercised with caution. The announcement date is 5 January 2024.